| Date | Title | Description | |
|---|---|---|---|
| 22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
| 29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 13 Nov 2020 | Other relevant information | The Company informs about the dividends payment | Download |
| 05 Nov 2020 | On business and financial situation | The company releases the press release related to the 2020 first nine months financial results | Download |
| 20 Oct 2020 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 15 Oct 2020 | Announcement of general shareholders’ meeting | In view of the exceptional circumstances derived from the spread of Covid-19, the Company has agreed that the Ordinary General Meeting be held by exclusively telematic means. | Download |
| 01 Oct 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2020 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Jul 2019 | R&D: new licenses, patents and registered trademarks | ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. | Download |
| 02 Jul 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2019 | Download |
| 26 Jun 2019 | Información sobre dividendos | The Company informs about the dividends payment | Download |
| 12 Jun 2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | Download |
| 08 May 2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its 2019 General Shareholders Meeting | Download |